查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830964

肺部給藥系統市場

Pulmonary Drug Delivery Systems Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

預計肺部給藥系統市場將從 2024 年的 541.4 億美元成長到 2031 年的 731.4 億美元，2025 年至 2031 年的複合年成長率為 4.4%。

市場洞察與分析師觀點：肺部給藥系統旨在透過吸入將氣霧劑直接輸送至上皮細胞和呼吸道上皮。這些系統包括吸入器和霧化器等裝置，可將藥物輸送至肺部以治療呼吸系統疾病。肺部給藥裝置採用各種藥物劑型及輸送機制。需要使用這些裝置治療的主要呼吸系統疾病包括氣喘、慢性阻塞性肺病 (COPD)、急性呼吸道感染、過敏性鼻炎和囊性纖維化。呼吸系統疾病的盛行率不斷上升，加上企業的策略性舉措，正在推動肺部給藥系統市場的成長。值得注意的趨勢包括吸入器技術的進步，預計這些技術將在未來幾年進一步推動市場成長。

成長催化劑：肺部給藥系統領域的企業持續推行策略舉措，例如合作、協議、夥伴關係和新產品推出。這些策略能夠提升銷售額，擴大地域覆蓋，並提升服務更廣泛客戶群的能力。新產品的推出主要旨在提升安全性、用戶友善性和劑量準確性，以吸引更廣泛的患者群體。以下是肺部給藥系統市場的一些重要發展：

2021 年 9 月，BreatheSuite Inc. 的 BreatheSuite 定量吸入器 V1 獲得了美國 FDA 的 510(K) 許可，可用於處方藥和非處方藥。該設備透過自動監測氣喘和 COPD 患者的吸入依從性和技術並提供回饋，將標準定量吸入器轉變為智慧吸入器。 2021 年 6 月，Glenmark Pharmaceuticals Ltd 在英國推出了 Tiogiva，這是噻托溴銨乾粉吸入器的生物等效版本，用於治療 COPD。 2021 年 4 月，KINDEVA DRUG DELIVERY 與 Cambridge Healthcare Innovations Limited (CHI) 合作，開發和商業化 CHI 的 aeolus 乾粉吸入器 (DPI) 平台技術。 2020 年 12 月，數位健康創新者 AireHealth 的連接霧化器獲得了 510(k) 許可，這是一款攜帶式電子振動網狀霧化器，用於霧化液體藥物供患者吸入，以 VitalMed 的品牌銷售。 2020 年 9 月，葛蘭素史克公司和 Innoviva, Inc. 獲得 FDA 批准使用 Trelegy Ellipta 是美國首個針對 18 歲及以上氣喘和 COPD 患者的每日一次單吸入性三合一療法。因此，公司為保持競爭力而採取的策略性舉措和產品發布越來越多，正在推動肺部藥物輸送系統市場的成長。

策略洞察報告細分與範圍：肺部給藥系統市場分析涵蓋以下幾個面向：產品、適應症、配銷通路、最終用戶和地理。產品領域包括乾粉吸入器、霧化器和定量吸入器。適應症領域分為慢性阻塞性肺病、氣喘、囊性纖維化等。配銷通路領域包括醫院藥房、零售藥房和電子商務。最終用戶領域分為醫院和診所以及家庭護理。肺部藥物輸送系統市場報告的範圍涵蓋北美（美國、加拿大和墨西哥）、歐洲（法國、德國、英國、西班牙、義大利和歐洲其他地區）、亞太地區（中國、日本、印度、韓國、澳洲和亞太其他地區）、中東和非洲（沙烏地阿拉伯、南非、阿拉伯聯合大公國和中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷和南美洲和其他地區）。

細分分析：肺部給藥系統市場依產品分為乾粉吸入器、霧化器和定量吸入器。乾粉吸入器細分市場在2023年佔據了相當大的市場佔有率，預計在2023年至2031年期間的複合年成長率最高。

根據適應症，肺部給藥系統市場分為慢性阻塞性肺病、氣喘、囊性纖維化等。慢性阻塞性肺病領域在2023年佔據了顯著的市場佔有率，預計在2023年至2031年期間將經歷最高的複合年成長率。

就配銷通路而言，市場細分為醫院藥房、零售藥房和電商。 2023年，醫院藥局佔據了肺部給藥系統市場的很大佔有率，而電商預計將在2023年至2031年期間實現最高的複合年成長率。

就終端用戶而言，肺部給藥系統市場分為醫院和診所以及家庭護理。醫院和診所在2023年佔據了相當大的市場佔有率，而家庭護理市場預計在2023年至2031年期間將實現更高的複合年成長率。

區域分析：從地理上講，肺部給藥系統市場分為北美、歐洲、亞太地區、南美和中美以及中東和非洲。 2023 年，北美佔據了相當大的市場佔有率，其中美國是該地區最大的貢獻者。北美市場的成長是由氣喘和 COPD 等呼吸系統疾病的盛行率不斷上升、老齡人口不斷成長、診斷設備需求不斷成長以及主要市場參與者的強大影響力所推動的。根據美國疾病管制與預防中心 (CDC) 2020 年的數據，美國約有 5.0% 的成年人被診斷出患有 COPD 或慢性支氣管炎，約有 2500 萬人患有氣喘，1480 萬人患有 COPD。此外，加拿大護理師協會估計，約有 300 萬加拿大人患有嚴重的呼吸系統疾病，包括 COPD、囊性纖維化、氣喘和職業性肺病。

加拿大肺臟協會報告稱，呼吸系統疾病是住院率第三高的疾病，約五分之一的加拿大人患有嚴重的呼吸系統疾病，例如氣喘、慢性阻塞性肺病、肺癌、肺結核、囊性纖維化和呼吸窘迫症候群。各種呼吸系統疾病患者數量的不斷增加，推動了對創新有效的肺部給藥系統（例如定量吸入器和霧化器）的需求。

肺部給藥系統市場報告範圍：產業發展與未來機會：肺部給藥系統市場報告包含對公司定位和集中度的分析，以評估競爭格局。根據各公司新聞稿，以下是市場主要參與者採取的一些措施：

2021年3月，PARI Pharma GmbH獲得LAMIRA霧化器系統的授權，用於在日本輸送Insmed的藥品ARIKAYCE（阿米卡星脂質體吸入混懸液）。此前，美國和歐洲已批准了ARIKAYCE，Insmed也於2021年3月獲得日本厚生勞動省的批准。 2020年12月，歐盟委員會批准阿斯特捷利康的Trixeo Aerosphere在歐盟用於治療慢性阻塞性肺病（COPD），該藥物專為中度至重度COPD成年患者設計。 Trixeo Aerosphere是一種單吸入器，由富馬酸福莫特羅、格隆溴銨和布地奈德組成，透過加壓定量吸入器輸送。競爭格局與關鍵參與者：肺部給藥系統市場的預測可以幫助利害關係人規劃其成長策略。市場的主要參與者包括阿斯特捷利康、葛蘭素史克、諾華、荷蘭皇家飛利浦、勃林格殷格翰國際有限公司、西普拉公司、歐姆龍公司、PARI GmbH、Glenmark Pharmaceuticals 和 Gilbert Technologies。這些公司專注於推出新的高科技產品、增強現有產品組合併拓展業務範圍，以滿足日益成長的全球消費者需求。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：肺部給藥系統市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：肺部給藥系統市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：肺部給藥系統市場－全球市場分析

  • 肺部給藥系統－全球市場概覽
  • 肺部給藥系統－全球市場及2031年預測

第7章：肺部給藥系統市場-收入分析-按產品，2021-2031

  • 概述
  • 乾粉吸入器
  • 定量吸入器
  • 霧化器

第 8 章：肺部給藥系統市場 - 收入分析 - 按適應症，2021-2031 年

  • 概述
  • 慢性阻塞性肺臟疾病
  • 氣喘
  • 囊腫纖維化
  • 其他

第9章：肺部給藥系統市場-收入分析-按配銷通路，2021-2031

  • 概述
  • 醫院藥房
  • 零售藥局
  • 電子商務

第 10 章：肺部給藥系統市場 - 收入分析 - 按最終用戶，2021-2031 年

  • 概述
  • 醫院和診所
  • 居家護理

第 11 章：肺部給藥系統市場 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 12 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 13 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 14 章：肺部給藥系統市場 - 關鍵公司簡介

  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • Koninklijke Philips NV
  • Cipla Inc.
  • OMRON Corp.
  • PARI GmbH
  • Glenmark Pharmaceuticals
  • Gilbert Technologies

第 15 章：附錄

簡介目錄
Product Code: TIPHE100001256

The pulmonary drug delivery systems market is anticipated to grow from US$ 54.14 billion in 2024 to US$ 73.14 billion by 2031, reflecting a CAGR of 4.4% from 2025 to 2031.

Market Insights and Analyst Perspective:Pulmonary drug delivery systems are designed to administer aerosols directly to the epithelial cells and respiratory epithelium via inhalation. These systems encompass devices like inhalers and nebulizers that deliver medications to the lungs for treating respiratory conditions. Various drug formulations and delivery mechanisms are utilized in pulmonary drug delivery devices. Key respiratory diseases necessitating these devices include asthma, chronic obstructive pulmonary disease (COPD), acute respiratory infections, allergic rhinitis, and cystic fibrosis. The rising prevalence of respiratory diseases, along with strategic initiatives from companies, is driving the growth of the pulmonary drug delivery systems market. Notable trends include advancements in inhaler technologies that are expected to further boost market growth in the coming years.

Growth Catalysts:Firms in the pulmonary drug delivery systems sector are consistently pursuing strategic initiatives such as collaborations, agreements, partnerships, and new product introductions. These strategies enhance their sales, expand their geographic presence, and improve their ability to cater to a larger customer base. New product launches are primarily aimed at enhancing safety, user-friendliness, and dosing accuracy to attract a broader patient demographic. Below are some significant developments in the pulmonary drug delivery systems market:

In September 2021, BreatheSuite Inc. obtained 510(K) clearances from the US FDA for its BreatheSuite metered-dose inhaler V1, intended for both prescription and over-the-counter use. This device transforms standard metered-dose inhalers into smart inhalers by automatically monitoring and providing feedback on inhaler adherence and technique for asthma and COPD patients.

In June 2021, Glenmark Pharmaceuticals Ltd launched Tiogiva, a bioequivalent version of Tiotropium Bromide dry powder inhaler, in the UK for COPD treatment.

In April 2021, KINDEVA DRUG DELIVERY partnered with Cambridge Healthcare Innovations Limited (CHI) to develop and commercialize CHI's aeolus dry-powder inhaler (DPI) platform technology.

In December 2020, AireHealth, a digital health innovator, received 510(k) clearance for its connected nebulizer, a portable electronic vibrating mesh nebulizer designed for nebulizing liquid medications for patient inhalation, marketed as VitalMed.

In September 2020, GlaxoSmithKline plc and Innoviva, Inc. secured FDA approval for Trelegy Ellipta, the first once-daily single inhaler triple therapy for asthma and COPD patients aged 18 and older in the US.Therefore, the increasing number of strategic initiatives and product launches by companies to maintain competitiveness is driving the growth of the pulmonary drug delivery systems market.

Strategic Insights

Report Segmentation and Scope:The analysis of the pulmonary drug delivery systems market has been conducted by examining the following segments: product, indication, distribution channel, end user, and geography. The product segment includes dry powder inhalers, nebulizers, and metered dose inhalers. The indication segment is classified into chronic obstructive pulmonary diseases, asthma, cystic fibrosis, and others. The distribution channel segment includes hospital pharmacies, retail pharmacies, and e-commerce. The end user segment is divided into hospitals & clinics and homecare. The scope of the pulmonary drug delivery systems market report encompasses North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:The pulmonary drug delivery systems market is categorized by product into dry powder inhalers, nebulizers, and metered dose inhalers. The dry powder inhalers segment accounted for a significant market share in 2023 and is expected to exhibit the highest CAGR from 2023 to 2031.

By indication, the pulmonary drug delivery systems market is classified into chronic obstructive pulmonary diseases, asthma, cystic fibrosis, and others. The chronic obstructive pulmonary diseases segment held a notable market share in 2023 and is projected to experience the highest CAGR during 2023 to 2031.

In terms of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment captured a significant share of the pulmonary drug delivery systems market in 2023, while the e-commerce segment is anticipated to achieve the highest CAGR from 2023 to 2031.

Regarding end user, the pulmonary drug delivery systems market is divided into hospitals & clinics and homecare. The hospitals & clinics segment held a substantial market share in 2023, whereas the homecare segment is expected to register a higher CAGR during 2023 to 2031.

Regional Analysis:Geographically, the pulmonary drug delivery systems market is divided into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2023, North America held a significant market share, with the US being the largest contributor in the region. The growth of the market in North America is driven by the increasing prevalence of respiratory diseases such as asthma and COPD, a growing elderly population, rising demand for diagnostic devices, and the strong presence of key market players. According to the Centers for Disease Control and Prevention (CDC) in 2020, approximately 5.0% of adults in the US are diagnosed with COPD or chronic bronchitis, with around 25 million individuals affected by asthma and 14.8 million suffering from COPD. Additionally, the Canadian Nurse Association estimates that about 3 million Canadians are afflicted with serious respiratory diseases, including COPD, cystic fibrosis, asthma, and occupational lung diseases.

The Canadian Lung Association reports that respiratory diseases account for the third highest rate of hospitalizations, with approximately one in five Canadians suffering from serious respiratory conditions such as asthma, COPD, lung cancer, tuberculosis, cystic fibrosis, and respiratory distress syndrome. The increasing number of patients with various respiratory diseases is driving the demand for innovative and effective pulmonary drug delivery systems, such as metered dose inhalers and nebulizers.

Pulmonary Drug Delivery Systems Market Report Scope

Industry Developments and Future Opportunities:The pulmonary drug delivery systems market report includes an analysis of company positioning and concentration to assess the competitive landscape. Based on company press releases, here are some initiatives undertaken by key players in the market:

In March 2021, PARI Pharma GmbH received authorization for the LAMIRA Nebulizer System to deliver Insmed's drug product ARIKAYCE (amikacin liposome inhalation suspension) in Japan. Insmed received approval for ARIKAYCE from Japan's Ministry of Health, Labour, and Welfare in March 2021, following earlier approvals in the US and Europe.

In December 2020, the European Commission approved AstraZeneca's Trixeo Aerosphere for COPD treatment in the European Union, designed for adult patients with moderate to severe COPD. Trixeo Aerosphere is a single-inhaler, fixed-dose combination of formoterol fumarate, glycopyrronium bromide, and budesonide, delivered via a pressurized metered-dose inhaler.

Competitive Landscape and Key Players:The forecast for the pulmonary drug delivery systems market can assist stakeholders in planning their growth strategies. Key players in the market include AstraZeneca, GlaxoSmithKline Plc, Novartis AG, Koninklijke Philips NV, Boehringer Ingelheim International GmbH, Cipla Inc., OMRON Corp., PARI GmbH, Glenmark Pharmaceuticals, and Gilbert Technologies. These companies are focused on launching new high-tech products, enhancing existing offerings, and expanding geographically to meet the increasing global consumer demand.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Pulmonary Drug Delivery Systems Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Pulmonary Drug Delivery Systems Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Pulmonary Drug Delivery Systems Market - Global Market Analysis

  • 6.1 Pulmonary Drug Delivery Systems - Global Market Overview
  • 6.2 Pulmonary Drug Delivery Systems - Global Market and Forecast to 2031

7. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By Product, 2021-2031

  • 7.1 Overview
  • 7.2 Dry Powder Inhalers
  • 7.3 Metered Dose Inhalers
  • 7.4 Nebulizers

8. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By Indication, 2021-2031

  • 8.1 Overview
  • 8.2 Chronic Obstructive Pulmonary Disease
  • 8.3 Asthma
  • 8.4 Cystic Fibrosis
  • 8.5 Others

9. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 E-commerce

10. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By End User, 2021-2031

  • 10.1 Overview
  • 10.2 Hospitals and Clinics
  • 10.3 Homecare

11. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Pulmonary Drug Delivery Systems Market Overview
    • 11.1.2 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts to 2031
    • 11.1.3 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Product
    • 11.1.4 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Indication
    • 11.1.5 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 11.1.6 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By End User
    • 11.1.7 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Countries
      • 11.1.7.1 United States Pulmonary Drug Delivery Systems Market
        • 11.1.7.1.1 United States Pulmonary Drug Delivery Systems Market, by Product
        • 11.1.7.1.2 United States Pulmonary Drug Delivery Systems Market, by Indication
        • 11.1.7.1.3 United States Pulmonary Drug Delivery Systems Market, by Distribution Channel
        • 11.1.7.1.4 United States Pulmonary Drug Delivery Systems Market, by End User
      • 11.1.7.2 Canada Pulmonary Drug Delivery Systems Market
        • 11.1.7.2.1 Canada Pulmonary Drug Delivery Systems Market, by Product
        • 11.1.7.2.2 Canada Pulmonary Drug Delivery Systems Market, by Indication
        • 11.1.7.2.3 Canada Pulmonary Drug Delivery Systems Market, by Distribution Channel
        • 11.1.7.2.4 Canada Pulmonary Drug Delivery Systems Market, by End User
      • 11.1.7.3 Mexico Pulmonary Drug Delivery Systems Market
        • 11.1.7.3.1 Mexico Pulmonary Drug Delivery Systems Market, by Product
        • 11.1.7.3.2 Mexico Pulmonary Drug Delivery Systems Market, by Indication
        • 11.1.7.3.3 Mexico Pulmonary Drug Delivery Systems Market, by Distribution Channel
        • 11.1.7.3.4 Mexico Pulmonary Drug Delivery Systems Market, by End User
  • 11.2 Europe
    • 11.2.1 Germany
    • 11.2.2 France
    • 11.2.3 Italy
    • 11.2.4 Spain
    • 11.2.5 United Kingdom
    • 11.2.6 Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1 Australia
    • 11.3.2 China
    • 11.3.3 India
    • 11.3.4 Japan
    • 11.3.5 South Korea
    • 11.3.6 Rest of Asia-Pacific
  • 11.4 Middle East and Africa
    • 11.4.1 South Africa
    • 11.4.2 Saudi Arabia
    • 11.4.3 U.A.E
    • 11.4.4 Rest of Middle East and Africa
  • 11.5 South and Central America
    • 11.5.1 Brazil
    • 11.5.2 Argentina
    • 11.5.3 Rest of South and Central America

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Pulmonary Drug Delivery Systems Market - Key Company Profiles

  • 14.1 AstraZeneca plc
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Boehringer Ingelheim International GmbH
  • 14.3 GlaxoSmithKline plc
  • 14.4 Novartis AG
  • 14.5 Koninklijke Philips NV
  • 14.6 Cipla Inc.
  • 14.7 OMRON Corp.
  • 14.8 PARI GmbH
  • 14.9 Glenmark Pharmaceuticals
  • 14.10 Gilbert Technologies

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud